Experimental Drug Improved Heart Function in Genetic Study
Adults with a rare form of muscular dystrophy showed significant cardiac improvements after one year of treatment.
Updated on Oct. 5, 2026 in Heart Disease
Live Poll
Do you trust that pharmaceutical companies are effectively developing cures for rare genetic diseases?
BridgeBio Pharma presented 12-month interim data from the Phase 3 FORTIFY trial, showing that their drug BBP-418 helped normalize heart muscle injury markers and stabilized heart function in patients with LGMD2I/R9. This potential disease-modifying therapy could change how this rare muscle condition is managed.
Why it matters
LGMD2I/R9 is a rare condition that causes progressive muscle weakness and cardiac issues, and BBP-418 aims to address the root cause by restoring the glycosylation of alpha-dystroglycan. This development represents a potential move toward treatment that could slow or prevent heart damage for those living with the disease.
In the Phase 3 FORTIFY trial, researchers tracked cardiac markers in patients with LGMD2I/R9 over 12 months. Results showed that 54% of treated individuals experienced stable or improved left ventricular ejection fraction, compared to 25% in the placebo group.
The players
BridgeBio Pharma
A biopharmaceutical company focused on developing genetic medicines for rare diseases and high-burden conditions.
FDA
The federal agency responsible for overseeing the safety and efficacy of medical products in the United States.
The details
BBP-418 works by saturating the partially functional FKRP enzyme with substrate, which enhances residual enzymatic function and restores the proper glycosylation of alpha-dystroglycan. Researchers used high-sensitivity troponin I blood tests to measure injury to the heart muscle, a key indicator of cardiac strain in LGMD2I/R9. By restoring this biological process, the drug seeks to mitigate the annual decline in cardiac performance that often affects these patients.
Timeline
Month 3: BBP-418 increased mean glycosylated alpha-dystroglycan.
Month 12: Exploratory interim cardiac analysis concluded.
October 5, 2026: BridgeBio presented FORTIFY data at World Muscle Society.
November 27, 2026: FDA target action date for BBP-418 approval.
First half of 2027: Planned initiation of studies for children under 12.
Health Landscape
The FORTIFY trial marks a significant step in the evolving research arc for limb-girdle muscular dystrophies, which historically lacked disease-modifying therapies. This effort shifts the treatment paradigm from symptom management toward interventions that target the underlying genetic causes.
If you or a family member are living with LGMD2I/R9, these findings highlight the importance of monitoring cardiac markers like troponin I and ejection fraction regularly with a specialist. It is worth discussing these trial results with your physician to understand how new therapies for rare conditions might fit into future care plans.
The takeaway
This study suggests that targeting the underlying enzyme deficiency in LGMD2I/R9 can lead to measurable improvements in heart muscle health. Patients and caregivers should track upcoming regulatory news from the FDA and consult their specialists about how emerging data on cardiac stability impacts long-term care management.
What happens next
The FDA is scheduled to announce a decision on the approval of BBP-418 on November 27, 2026. Following this, BridgeBio expects to begin clinical studies for children under 12 in the first half of 2027.
Further reading
For more on the current research surrounding complex cardiac conditions, visit our Heart Disease section.
Live Poll
Do you trust that pharmaceutical companies are effectively developing cures for rare genetic diseases?
